Atopic dermatitis has entered the precision-medicine era unevenly, and a new Dermatology Times review, "Precision Medicine in Atopic Dermatitis: Current Challenges and Future Directions," takes stock of exactly where the gaps remain. The piece frames a field that has moved fast on therapeutics and slower on matching the right drug to the right patient.

AD is no longer one disease in the clinic's eyes. The review rests on a now-standard premise: atopic dermatitis is a heterogeneous condition with distinct endotypes, and treatment decisions increasingly reflect that biology rather than a one-size-fits-all topical-first ladder.

What has precision medicine already delivered?

The last several years changed the treatment map. Biologics targeting IL-4 and IL-13 signaling, plus oral JAK inhibitors, gave clinicians mechanistically defined options for moderate-to-severe disease after decades dominated by topical corticosteroids and emollients.

That shift is real. It's also incomplete. The review's central argument is that having targeted agents is not the same as having precision — clinicians still lack validated tools to predict which patient will respond to which mechanism before they prescribe.

The takeaway: targeted drugs arrived; patient-level targeting is still catching up.

What stands in the way?

The review catalogs the field's open problems rather than smoothing them over:

• Biomarker scarcity. No validated, routine biomarker yet tells a dermatologist upfront whether a given patient will respond to a biologic or a JAK inhibitor.
• Endotype complexity. Multiple immune pathways drive AD across patients, and the dominant pathway in one patient may be marginal in another.
• Phenotype heterogeneity. Age of onset, lesion morphology, skin tone and disease chronicity all vary, complicating trial-to-clinic translation.
• Access and cost. Precision tools and newer agents carry price tags that not every practice or patient can absorb.

Each of these is a solvable problem. None is solved today.

The takeaway: the bottleneck has shifted from drug discovery to patient stratification.

Where is the field heading?

The "future directions" half of the review points toward what most investigators in AD now expect: biomarker-driven stratification, deeper endotyping of individual patients, and treatment algorithms that incorporate patient-specific immune profiling rather than stepwise trial and error.

The clinical promise is straightforward. A patient with severe AD could one day receive the agent most likely to clear her disease on the first try, instead of cycling through options while EASI scores lag. That scenario isn't here yet, and the review doesn't pretend it is.

The takeaway: the next gains in AD care will come from prediction, not from new molecules alone.

Why this matters for practice

For clinicians, the review is a status check. It confirms that current guidelines and real-world practice already sit on heterogeneous biology, and that the tools to resolve that heterogeneity at the bedside are still in development.

For researchers and industry, it reads as a prioritization document. The unmet need it names is specific: validated response-prediction biomarkers and practical stratification frameworks for AD, worked out well enough to move from cohorts into routine care.

The direction of travel is clear even if the timeline isn't — precision in atopic dermatitis is advancing from broad mechanistic targeting toward genuinely individualized treatment selection, and the pace of that shift will depend on the biomarker work now underway.